Ken Lawless is the CEO of BDR Technologies, an Ottawa-based clean energy technology company, as well as the President of Epitope Capital, a privately held consulting company.
Ken has been very active in promoting investment in, and the commercialization of, life sciences companies and technologies. He was the founding President of the Ottawa Life Sciences Council (OLSC) since its inception (May 1994) until June 2006, when it amalgamated with the Ottawa Centre for Research and Innovation. He has also served as Interim President of the Ottawa Life Sciences Technology Park and was a Founding Director of the Ottawa Biotechnology Incubation Centre.
Ken holds a Master’s Degree in Biochemistry from the University of Ottawa and has conducted research in the hormonal control of gene expression, prostate cancer and artificial blood substitutes.
He has served on provincial, federal and local boards and committees, including; the National Research Council of Canada’s Innovation Forum and National Bioproducts Initiative, the Ontario Biotechnology Task Force, BIOTECanada’s Science and Technology Committee, the Canadian Foundation for Innovation (CFI) Multidisciplinary Advisory Committee, the Board of the Ottawa General Hospital Research Institute, and the Ottawa Biotechnology Innovation Fund. He currently sits on the Board of the Health Technology Exchange (HTX) and is a Committee Member of the American Society of Testing and Measurement (ASTM).
In 2002, Ken was chosen by Ottawa Life Magazine as one of Ottawa’s 50 most influential individuals.